RxDoctor Payments Data

Kenneth Sabatino, MD

Cardiovascular Disease · Safety Harbor, FLNPI 1003805664

Payments from drug & device makers

$520,931in general payments, 2019–2025

Across 594 payments — averaging $876.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$130K
  • Boehringer Ingelheim International GmbH$123K
  • CSL Behring$90K
  • Esperion Therapeutics, Inc.$88K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$41K
  • Bayer$26K
  • plus $23K from 23 others

What the payments were for

  • Food & beverage$3,34897%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$520,931 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$515,530
Medicare patients
2,395
Services billed
6,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban574$700,774
Repatha SureclickEvolocumab169$161,751
XareltoRivaroxaban135$139,603
EntrestoSacubitril/Valsartan66$102,965
FarxigaDapagliflozin Propanediol41$53,004
BrilintaTicagrelor36$39,476
VascepaIcosapent Ethyl35$19,124
Praluent PenAlirocumab22$14,993
JardianceEmpagliflozin12$12,091
Nebivolol Hcl167$11,295
Rosuvastatin Calcium721$8,191
Ezetimibe256$6,653
Metoprolol Succinate507$6,456
Flecainide Acetate126$5,664
Carvedilol513$5,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$700,774574 claims
Johnson & JohnsonXarelto$79$139,603135 claims
NovartisEntresto$120$102,96566 claims
AstraZenecaFarxiga, Brilinta$400$92,48077 claims
Boehringer IngelheimJardiance$30$12,09112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Safety Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →